Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Cynomolgus LAG-3 / CD223 Protein, Mouse IgG2a Fc Tag, 100µg  

Recombinant Cynomolgus LAG-3 / CD223 Protein, Mouse IgG2a Fc Tag, 100µg

Recombinant Cynomolgus LAG-3 / CD223, Ala 18 - His 449,  expressed from human 293 cells (HEK293), Mouse IgG2a Fc Tag

Synonym
recombinant, cynomolgus, protein, LAG3,CD223,FDC

More details

LA3-C52A0-100

Availability: within 7 days

533,00 €

Background
Lymphocyte activation gene 3 protein (LAG3) is also known as CD antigen CD223 and protein FDC, which belongs to immunoglobulin (Ig) superfamily and contains 4 extracellular Ig-like domains. The LAG3 gene contains 8 exons. The sequence data, exon/intron organization, and chromosomal localization all indicate a close relationship of LAG3 to CD4. LAG3 /CD223 involved in lymphocyte activation. LAG3 /CD223 binds to HLA class-II antigens.

Source
Recombinant Cynomolgus LAG-3 / CD223, Mouse IgG2a Fc Tag (LA3-C52A0) is expressed from human 293 cells (HEK293). It contains AA Ala 18 - His 449 (Accession # XP_005570011.1).
Predicted N-terminus: Ala 18

Molecular Characterization
This protein carries a mouse IgG2a Fc tag at the C-terminus.
The protein has a calculated MW of 73.5 kDa. The protein migrates as 95 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>90% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Characterisation of the protein expression of the emerging immunotherapy targets VISTA, LAG-3 and PRAME in primary uveal melanoma: insights from a southern French patient cohort"
Lamas, Lassalle, Martel et al
Pathology (2023)
(2) "In vitro vascularized immunocompetent patient-derived model to test cancer therapies"
Lê, Deforges, Hua et al
iScience (2023) 26 (10), 108094
(3) "The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial"
Luke, Patel, Blumenschein et al
Nat Med (2023)
Showing 1-3 of 1488 papers.

Citations

(1) "Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy"
Authors: X Yu, et al
Journal: MAbs 2019
Application: BLI
(2) "Antibodies binding lag-3 and uses thereof"
Authors: X Kang, et al
Journal: US20190016800A1 2019
Application: BLI